Stuart J. Connolly

81.3k total citations · 26 hit papers
474 papers, 47.0k citations indexed

About

Stuart J. Connolly is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, Stuart J. Connolly has authored 474 papers receiving a total of 47.0k indexed citations (citations by other indexed papers that have themselves been cited), including 435 papers in Cardiology and Cardiovascular Medicine, 75 papers in Internal Medicine and 42 papers in Surgery. Recurrent topics in Stuart J. Connolly's work include Atrial Fibrillation Management and Outcomes (308 papers), Cardiac Arrhythmias and Treatments (217 papers) and Cardiac electrophysiology and arrhythmias (124 papers). Stuart J. Connolly is often cited by papers focused on Atrial Fibrillation Management and Outcomes (308 papers), Cardiac Arrhythmias and Treatments (217 papers) and Cardiac electrophysiology and arrhythmias (124 papers). Stuart J. Connolly collaborates with scholars based in Canada, United States and Germany. Stuart J. Connolly's co-authors include Salim Yusuf, John W. Eikelboom, Michael D. Ezekowitz, Lars Wallentin, Paul Reilly, Stefan H. Hohnloser, Jeff S. Healey, Michael Gent, Jonas Oldgren and Janice Pogue and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Stuart J. Connolly

461 papers receiving 45.0k citations

Hit Papers

Dabigatran versus Warfarin in Pat... 1983 2026 1997 2011 2009 2012 2010 2000 2013 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dabigatran versus Warfarin in Patients with Atrial Fibrillation
    2009 8.0k citations Stuart J. Connolly, Michael D. Ezekowitz et al. profile →
  2. Subclinical Atrial Fibrillation and the Risk of Stroke
    2012 1.4k citations Jeff S. Healey, Stuart J. Connolly et al. profile →
  3. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
    2010 1.2k citations Mario Talajic, Stuart J. Connolly et al. profile →
  4. Canadian Implantable Defibrillator Study (CIDS)
    2000 1.0k citations Stuart J. Connolly, Denis‐Claude Roy et al. Circulation profile →
  5. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
    2013 948 citations John W. Eikelboom, Stuart J. Connolly et al. profile →
  6. Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction
    2004 894 citations Stefan H. Hohnloser, Eric Fain et al. profile →
  7. Canadian atrial fibrillation anticoaguiation (CAFA) study
    1991 831 citations Stuart J. Connolly et al. Journal of the American College of Cardiology profile →
  8. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
    2011 822 citations John W. Eikelboom, Lars Wallentin et al. Circulation profile →
  9. Amiodarone to Prevent Recurrence of Atrial Fibrillation
    2000 774 citations Denis‐Claude Roy, Mario Talajic et al. profile →
  10. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
    2015 732 citations Stuart J. Connolly et al. profile →
  11. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
    2010 728 citations Lars Wallentin, Salim Yusuf et al. profile →
  12. Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
    2009 707 citations Stefan H. Hohnloser, Harry J.G.M. Crijns et al. profile →
  13. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome
    1983 658 citations Stuart J. Connolly et al. The American Journal of Cardiology profile →
  14. Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
    2008 640 citations Stuart J. Connolly, Janice Pogue et al. Circulation profile →
  15. The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
    2013 630 citations Paul Reilly, Stuart J. Connolly et al. Journal of the American College of Cardiology profile →
  16. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
    1997 607 citations Stuart J. Connolly et al. profile →
  17. CYCLICAL VARIATION OF THE HEART RATE IN SLEEP APNOEA SYNDROME
    1984 454 citations Stuart J. Connolly et al. profile →
  18. Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events
    2014 444 citations Michela Brambatti, Stuart J. Connolly et al. Circulation profile →
  19. Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2)
    2014 435 citations Carlos A. Morillo, Stuart J. Connolly et al. profile →
  20. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin
    2012 399 citations Jeff S. Healey, John W. Eikelboom et al. Circulation profile →
  21. Embolic Stroke of Undetermined Source
    2017 376 citations Robert G. Hart, Kanjana Perera et al. Stroke profile →
  22. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT
    2017 363 citations Jeff S. Healey, Harry J.G.M. Crijns et al. European Heart Journal profile →
  23. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
    2014 347 citations Stuart J. Connolly, Jeff S. Healey et al. profile →
  24. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
    2016 330 citations Ziad Hijazi, Jonas Oldgren et al. profile →
  25. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease
    2018 269 citations John W. Eikelboom, Jackie Bosch et al. Journal of the American College of Cardiology profile →
  26. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials
    2023 100 citations Alexander P. Benz, Jeff S. Healey et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stuart J. Connolly Canada 100 42.2k 11.2k 5.2k 4.6k 2.4k 474 47.0k
Michael D. Ezekowitz United States 75 41.4k 1.0× 13.3k 1.2× 7.7k 1.5× 3.9k 0.9× 2.9k 1.2× 269 47.8k
Elaine M. Hylek United States 79 24.3k 0.6× 11.1k 1.0× 4.6k 0.9× 2.7k 0.6× 1.3k 0.6× 252 31.2k
Jonathan L. Halperin United States 88 29.0k 0.7× 9.5k 0.8× 6.2k 1.2× 3.3k 0.7× 2.8k 1.2× 305 35.1k
Kenneth W. Mahaffey United States 97 32.6k 0.8× 10.4k 0.9× 3.9k 0.8× 13.1k 2.8× 3.4k 1.4× 656 48.2k
Basil S. Lewis Israel 52 20.1k 0.5× 6.9k 0.6× 2.9k 0.6× 8.6k 1.9× 2.5k 1.0× 278 28.0k
Lars Wallentin Sweden 114 49.4k 1.2× 15.1k 1.4× 5.6k 1.1× 14.3k 3.1× 7.5k 3.2× 753 59.3k
Adrian F. Hernandez United States 99 26.2k 0.6× 3.0k 0.3× 7.8k 1.5× 6.3k 1.4× 1.8k 0.7× 899 42.2k
Robert G. Hart United States 69 17.9k 0.4× 5.7k 0.5× 8.1k 1.6× 1.9k 0.4× 1.8k 0.8× 226 24.5k
Manesh R. Patel United States 79 22.4k 0.5× 6.5k 0.6× 3.1k 0.6× 9.4k 2.0× 8.9k 3.7× 545 30.9k
Jonathan P. Piccini United States 76 24.1k 0.6× 6.9k 0.6× 2.9k 0.6× 1.9k 0.4× 1.4k 0.6× 547 26.3k

Countries citing papers authored by Stuart J. Connolly

Since Specialization
Citations

This map shows the geographic impact of Stuart J. Connolly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart J. Connolly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart J. Connolly more than expected).

Fields of papers citing papers by Stuart J. Connolly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart J. Connolly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart J. Connolly. The network helps show where Stuart J. Connolly may publish in the future.

Co-authorship network of co-authors of Stuart J. Connolly

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart J. Connolly. A scholar is included among the top collaborators of Stuart J. Connolly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart J. Connolly. Stuart J. Connolly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Johnson, Linda, Alexander P. Benz, Ashkan Shoamanesh, et al.. (2024). Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF. Journal of the American Heart Association. 13(17). e034758–e034758. 3 indexed citations
2.
Eikelboom, John W., Hardi Mundl, John H. Alexander, et al.. (2024). Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials. Journal of the American College of Cardiology. 83(6). 669–678. 4 indexed citations
3.
Benz, Alexander P., Stefan H. Hohnloser, John W. Eikelboom, et al.. (2023). Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. European Heart Journal. 44(20). 1807–1814. 23 indexed citations
4.
Millenaar, Dominic, Helmut Schumacher, Martina Brueckmann, et al.. (2021). Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). The American Journal of Cardiology. 149. 27–35. 15 indexed citations
5.
Ameriso, Sebastián F., Pierre Amarenco, Lesly A. Pearce, et al.. (2020). Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. Journal of Stroke and Cerebrovascular Diseases. 29(8). 104936–104936. 15 indexed citations
6.
Hijazi, Ziad, Paolo Verdecchia, Jonas Oldgren, et al.. (2019). Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: Experiences from the RE-LY trial. IrInSubria (University of Insubria). 15 indexed citations
7.
Bosch, Jackie, et al.. (2015). Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke. International Journal of Stroke. 10(7). 1031–1036. 41 indexed citations
8.
Brambatti, Michela, Stuart J. Connolly, Michael R. Gold, et al.. (2014). Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. Circulation. 129(21). 2094–2099. 444 indexed citations breakdown →
9.
Marijon, Éloi, Jean‐Yves Le Heuzey, Stuart J. Connolly, et al.. (2013). Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. Circulation. 128(20). 2192–2201. 226 indexed citations
10.
Majeed, Ammar, Hun-Gyu Hwang, Stuart J. Connolly, et al.. (2013). Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Circulation. 128(21). 2325–2332. 209 indexed citations
11.
Flaker, Greg C., John W. Eikelboom, Olga Shestakovska, et al.. (2012). Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. Stroke. 43(12). 3291–3297. 61 indexed citations
12.
Hijazi, Ziad, Jonas Oldgren, Ulrika Andersson, et al.. (2012). Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. Circulation. 125(13). 1605–1616. 304 indexed citations
13.
Spall, Harriette G.C. Van, Lars Wallentin, Salim Yusuf, et al.. (2012). Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. Circulation. 126(19). 2309–2316. 112 indexed citations
14.
Connolly, Stuart J., Paul Reilly, Janice Pogue, et al.. (2012). Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years : Results of the Rely-Able Double-Blind Randomized Trial. Circulation. 126(23). 2793–2793. 6 indexed citations
15.
Healey, Jeff S., John W. Eikelboom, James D. Douketis, et al.. (2012). Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. Circulation. 126(3). 343–348. 399 indexed citations breakdown →
16.
Hart, Robert G., Hans‐Christoph Diener, Sean Yang, et al.. (2012). Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran. Stroke. 43(6). 1511–1517. 313 indexed citations
17.
Dans, Antonio L., Stuart J. Connolly, Lars Wallentin, et al.. (2012). Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation. 127(5). 634–640. 344 indexed citations
18.
19.
Walraven, Carl van, Robert G. Hart, Stuart J. Connolly, et al.. (2009). Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation. Stroke. 40(4). 1410–1416. 234 indexed citations
20.
Sheldon, Robert S., Stuart J. Connolly, Sarah Rose, et al.. (2006). Prevention of Syncope Trial (POST). Circulation. 113(9). 1164–1170. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael D. Ezekowitz Breakdown of academic impact, for papers by Elaine M. Hylek Breakdown of academic impact, for papers by Jonathan L. Halperin Breakdown of academic impact, for papers by Kenneth W. Mahaffey Breakdown of academic impact, for papers by Basil S. Lewis Breakdown of academic impact, for papers by Lars Wallentin Breakdown of academic impact, for papers by Adrian F. Hernandez Breakdown of academic impact, for papers by Robert G. Hart Breakdown of academic impact, for papers by Manesh R. Patel Breakdown of academic impact, for papers by Jonathan P. Piccini
Rankless by CCL
2026